SUMO3

SUMO3 is a ubiquitin-like post-translational modifier that conjugates to target proteins via the SAE1/SAE2 E1 and Ubc9 E2 enzymatic cascade and forms polymeric chains through an internal ψKXE consensus site, a capacity shared with SUMO2 but not SUMO1 (PMID:11451954). SUMO3 modification regulates diverse nuclear processes including transcriptional synergy control (C/EBPα, C/EBPβ-1), PML nuclear body integrity, androgen receptor stability and degradation via PIAS1/MDM2-mediated ubiquitination, and innate immune signaling through MAVS aggregation-driven IFN-β induction and suppression of a noncanonical type I interferon response (PMID:12511558, PMID:15940266, PMID:31752909, PMID:31806367, PMID:29891701). Although SUMO3 is largely functionally redundant with SUMO2—Sumo3-null mice are viable whereas Sumo2-null embryos die at ~E10.5—combined dosage reduction reveals essential shared roles in development, and SUMO2/3 can compensate for SUMO1 loss in modifying canonical SUMO1 substrates such as RanGAP1 (PMID:24891386, PMID:19033381). The NMR solution structure of SUMO3 adopts a ββαββαβ ubiquitin fold, with a negatively charged β-sheet surface that mediates electrostatic recognition of Ubc9 (PMID:15723523).

1. 2001 High

   Establishing that SUMO2/3, unlike SUMO1, can form polymeric chains resolved how SUMO paralogs differ mechanistically and identified the ψKXE internal site as the basis for chain elongation via the SAE1/SAE2–Ubc9 cascade.

   Evidence In vitro reconstitution with purified E1/E2 and recombinant SUMO proteins plus in vivo chain detection

   PMID:11451954

   Open questions at the time

   • No E3 ligase involvement characterized for chain formation
   • Chain topology and length regulation undefined
   • Functional consequences of chains vs. mono-SUMO3 not separated
2. 2003 High

   Demonstrating that SUMO3 modifies transcription factors C/EBPα and C/EBPβ-1 at specific lysines established that SUMO3 conjugation directly regulates transcriptional output—limiting synergistic transactivation (C/EBPα) and mediating transcriptional repression (C/EBPβ-1).

   Evidence In vitro and in vivo SUMOylation assays with site-directed mutagenesis (K159R, K173R) coupled to transcriptional reporter assays

   PMID:12511558 PMID:12810706

   Open questions at the time

   • Mechanism by which SUMO3 at the synergy control motif attenuates transcription not defined
   • Chromatin-level effects not examined
3. 2005 High

   The NMR structure of SUMO3 and mapping of its Ubc9-binding surface revealed the electrostatic complementarity underlying E2 recognition, providing a structural basis for conjugation specificity.

   Evidence NMR solution structure determination with chemical shift perturbation mapping of the Ubc9 interface

   PMID:15723523

   Open questions at the time

   • No co-crystal structure of the SUMO3–Ubc9 complex
   • Structural basis for SUMO2 vs. SUMO3 discrimination by substrates not addressed
4. 2005 Medium

   Showing that SUMO3 is specifically required for PML nuclear body integrity—and that SUMO3 oligomerization is needed for PML nuclear retention—established a non-redundant isoform-specific role distinct from SUMO1 and SUMO2.

   Evidence siRNA depletion of SUMO3 with rescue by wild-type but not conjugation-defective SUMO3; immunofluorescence

   PMID:15940266

   Open questions at the time

   • Mechanism by which SUMO3 chains specifically retain PML in nuclear bodies not defined
   • Whether SUMO3 oligomerization acts via SIM-mediated interactions was not tested
5. 2005 Medium

   SUMO3 enhances androgen receptor transcriptional activity and prostate cancer cell proliferation through a conjugation-independent mechanism, revealing a non-covalent function for SUMO3.

   Evidence Mutational analysis of AR sumoylation sites and SUMO3 conjugation function; reporter assay and proliferation assay in LNCaP cells

   PMID:16361251

   Open questions at the time

   • Non-covalent mechanism of action uncharacterized
   • Direct binding partner mediating conjugation-independent effect unknown
6. 2008 Medium

   In vivo compensation by SUMO2/3 for SUMO1 loss in modifying RanGAP1 demonstrated broad functional redundancy among SUMO paralogs at the organismal level.

   Evidence SUMO1-null mouse with immunofluorescence and Western blot analysis of RanGAP1 and PML sumoylation status

   PMID:19033381

   Open questions at the time

   • Which E3 ligases redirect SUMO2/3 to SUMO1 targets not identified
   • Whether compensatory modification is qualitatively equivalent unclear
7. 2011 Medium

   Proteomic identification of 188 SUMO3 substrates under ischemia and the finding that SUMO2/3 silencing blocks stress-induced ubiquitination established a direct crosstalk between the SUMO3 and ubiquitin pathways under cellular stress.

   Evidence SILAC-based quantitative proteomics with HA-SUMO3 IP in neuroblastoma cells; siRNA-mediated SUMO2/3 depletion with ubiquitination readout

   PMID:22082260

   Open questions at the time

   • Individual SUMO3 substrates not validated by orthogonal methods
   • Molecular link between SUMO3 conjugation and ubiquitin ligase recruitment not identified
8. 2011 Medium

   Selective transcriptional downregulation of SUMO3 (but not SUMO2) by oxidative stress through Sp1 oxidation revealed that SUMO3 abundance is dynamically regulated, providing a mechanism for stress-dependent shifts in the SUMO2/3 ratio.

   Evidence qRT-PCR, promoter analysis, and ChIP for Sp1 binding under oxidative stress

   PMID:21291420

   Open questions at the time

   • Whether reduced SUMO3 alters the poly-SUMO chain landscape under stress not tested
   • Sp1 oxidation site not mapped
9. 2014 High

   Genetic analysis in mice established that SUMO3 is individually dispensable for viability but becomes essential in combination with reduced SUMO2, proving dosage-dependent functional redundancy rather than strict isoform-specific roles in development.

   Evidence Sumo2 and Sumo3 single and compound knockout mice; timed embryonic analysis

   PMID:24891386

   Open questions at the time

   • Specific developmental processes requiring SUMO2/3 dosage not identified
   • Whether tissue-specific expression differences contribute to the dosage requirement unclear
10. 2018 High

    SUMO2/3 were shown to actively suppress a noncanonical type I interferon response independent of known IFN-inducing pathways, positioning SUMOylation as a constitutive checkpoint on innate immune activation.

    Evidence SUMO2/3 genetic knockout combined with epistasis analysis using IRF3/IRF7 knockouts; IFN production assays

    PMID:29891701

    Open questions at the time

    • Identity of the SUMO2/3-modified target(s) that suppress noncanonical IFN unknown
    • Whether this reflects mono- vs. poly-SUMO modification not determined
11. 2019 Medium

    SUMO3 poly-chain conjugation to MAVS was shown to drive MAVS aggregation and IFN-β production in response to cytosolic DNA sensing, establishing a direct mechanistic link between SUMO3 chains and innate antiviral signaling.

    Evidence Co-IP of SUMO3-MAVS; MAVS aggregation assay; Ubc9 siRNA and ginkgolic acid inhibition; IFN-β ELISA in keratinocytes

    PMID:31806367

    Open questions at the time

    • SUMO3 conjugation sites on MAVS not mapped
    • E3 ligase mediating MAVS SUMO3 modification not identified
12. 2019 Medium

    SUMO3 modification of PIAS1 at K117 was shown to be required for AR cytoplasmic redistribution and MDM2-mediated AR ubiquitination and proteasomal degradation, establishing a SUMO3→ubiquitin→degradation cascade for AR.

    Evidence Site-directed mutagenesis of PIAS1 K117 and AR K386/K845; Co-IP; AR localization by immunostaining; degradation assays

    PMID:31752909

    Open questions at the time

    • Whether SUMO3 modification of PIAS1 alters its E3 ligase activity broadly or is AR-specific unknown
    • In vivo relevance in prostate tissue not tested
13. 2023 Medium

    Demonstrating that SUMO3 promotes TRIM55 degradation through SIM-dependent ubiquitination via both proteasomal and lysosomal routes generalized the SUMO3-to-ubiquitin degradation mechanism to a non-covalent (SIM-mediated) mode of action.

    Evidence SUMO3 overexpression; SIM mutagenesis in TRIM55; proteasome and lysosome inhibitor assays; polyubiquitination assay

    PMID:37703582

    Open questions at the time

    • Whether SUMO3 acts as a direct bridging factor or recruits a SUMO-targeted ubiquitin ligase (STUbL) for TRIM55 degradation not determined
    • Physiological context of TRIM55–SUMO3 interaction not established

• Key unresolved questions include: the identity of SUMO3-specific substrates vs. shared SUMO2/3 substrates at endogenous expression levels, the E3 ligases and deconjugases that confer SUMO3 specificity in innate immune signaling, and the structural basis for differential recognition of SUMO3 chains by SIM-containing effectors.
• No systematic endogenous-level SUMO3-specific substrate catalog exists
• SUMO3 chain readers/decoders not comprehensively identified
• No structural model of a SUMO3 poly-chain bound to a SIM-containing effector